Osteology and Rheumatology · Vol. 1, No. 1 · 2025 · pp. 14–15 · e-ISSN 2996-5918

A Novel Application for a Rheumatologic Medication

Charles F. Haller, Matthew B. Carroll, Christopher Smith, Yolanda Moulds-Love

Department of Rheumatology, Keesler Air Force Base Medical Center, 301 Fisher Av., Keesler AFB, MS 39534, USAUnited States

DOI: https://doi.org/10.17140/orhoj-1-e001 · Published 2025-09-11 · Licence: https://creativecommons.org/licenses/by/4.0 · © 2025 The Author(s)

Also available as PDF (figures and tables appear in the PDF).

Abstract

Rheumatology has enjoyed significant advances in pharmacotherapy over the past two decades. Now, with our arsenals buffered, we ask, “Can these novel anti-rheumatic drugs escape the niche of rheumatology? Is their utility beyond the joints and autoimmunological processes? Say perhaps, myocardial infarctions?”Enter tocilizumab (Actemra®). Tocilizumab is a novel humanized monoclonal anti-body approved by the US Food and Drug Administration in 2010 for the treatment of rheu-matoid arthritis and (later) juvenile idiopathic arthritis. The drug is administered as either a monthly intravenous infusion or as a weekly (or every other week) subcutaneous injection. The dose of the monthly infusion can vary between 4 mg/kg and 8 mg/kg but the once a week or every other week injection is 162 mg subcutaneously. In patients with rheumatoid arthritis, interleukin 6 (IL-6) is overproduced in the body, causing fatigue, anemia, inflammation and damage to bones, cartilage and tissue. Acting as an antagonist of IL-6 receptors, tocilizumab in-terferes with the pro-inflammatory effects of the IL-6–IL-6 receptor interaction. This response can be objectively gauged with serum C-Reactive Protein (CRP), offering a clinically practical and quantitative measure of inflammation.

Keywords: causing fatigue, anemia, inflammation and damage to bones, cartilage and tissue

Acknowledgements

I affirm that this manuscript has neither been

The views expressed in this material are those of the authors, and do not reflect the official policy or position of the US government, the Department of Defense, or the Department of the Air Force.

The voluntary, fully informed consent of the subjects used in this research was obtained as required by 32 CFR 219 and AFI 40-402, Protection of Human Subjects in Biomedical and Behavioral Research.

The work reported herein was performed under United States Air Force Surgeon General approved Clinical Investigation FKE 20140029H.

The authors have no financial disclosures.

This trial was registered with www.clinicaltrials.gov (NCT02419937)

References

  1. MiyaoYYasueHOgawaH. Elevated plasma interleukin-6 levels in patients with acute myocardial infarction. Am Heart J. 1993; 126(6): 1299-1304. doi: 10.1016/0002-8703(93)90526-F10.1016/0002-8703(93)90526-f https://doi.org/10.1016/0002-8703(93)90526-f
  2. GabrielASMartinssonAWretlindBAhnveS. IL-6 levels in acute and post myocardial infarction: their relation to CRP levels, infarction size, left ventricular systolic function, and heart failure. Eur J Intern Med. 2004; 15(8): 523-528. doi: 10.1016/j. ejim.2004.07.01310.1016/j.ejim.2004.07.013 https://doi.org/10.1016/j.ejim.2004.07.013
  3. López-Cuenca Á, Manzano-Fernández S, Lip GY, et al. Interleukin-6 and high-sensitivity C-reactive protein for the prediction of outcomes in non-ST-segment elevation acute rec.2012.07.019
  4. Zamani P, Schwartz GG, Olsson AG, Rifai N, Bao W, Libby P, Ganz P, Kinlay S; Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study after an acute coronary syndrome in the MIRACL study. J Am Heart Assoc. 2013; 2(1): e003103. doi: 10.1161/JAHA.112.003103 https://doi.org/10.1161/jaha.112.003103
  5. KarpińskiLPłaksejRKosmalaWWitkowskaM. Serum levels of interleukin-6, interleukin-10 and C-reactive protein in relation to left ventricular function in patients with myocardial infarction treated with primary angioplasty. Kardiol Pol. 2008; 66(12): 1279-1285. submitted nor is simultaneously being submitted elsewhere. coronary syndromes. Rev Esp Cardiol (Engl Ed). 2013; 66(3): 185-192. doi: 10.1016/j. Investigators. Inflammatory biomarkers, death, and recurrent nonfatal coronary events10.1016/j.investigators https://doi.org/10.1016/j.investigators